Aptose Biosciences price target lowered to $8 from $13 at Canaccord
The Fly

Aptose Biosciences price target lowered to $8 from $13 at Canaccord

Canaccord lowered the firm’s price target on Aptose Biosciences to $8 from $13 and keeps a Buy rating on the shares. The analyst reduced the target due to our lowering of probability of success for luxeptinib in light of the company’s focus on the lead asset, tuspetinib. Canaccord said we continue to base our PT off of expectations for further clinical activity for HM43239 in AML and for luxeptinib in AML and B-cell malignancies at higher doses.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on APTO:

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TipRanks Auto-Generated NewsdeskAptose Biosciences Shareholders Endorse Key Resolutions
GlobeNewswireAptose Announces Results from Special Meeting of Shareholders
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App